Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.13
TBIO's Cash to Debt is ranked lower than
53% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. TBIO: 0.13 )
TBIO' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.13

Equity to Asset 0.33
TBIO's Equity to Asset is ranked higher than
53% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. TBIO: 0.33 )
TBIO' s 10-Year Equity to Asset Range
Min: -0.46   Max: 0.95
Current: 0.33

-0.46
0.95
F-Score: 2
Z-Score: -7.77
M-Score: -2.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -59.02
TBIO's Operating margin (%) is ranked higher than
60% of the 247 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. TBIO: -59.02 )
TBIO' s 10-Year Operating margin (%) Range
Min: -57.78   Max: -1.53
Current: -59.02

-57.78
-1.53
Net-margin (%) -47.38
TBIO's Net-margin (%) is ranked higher than
60% of the 247 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. TBIO: -47.38 )
TBIO' s 10-Year Net-margin (%) Range
Min: -136.16   Max: -2.06
Current: -47.38

-136.16
-2.06
ROE (%) -98.28
TBIO's ROE (%) is ranked higher than
50% of the 225 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. TBIO: -98.28 )
TBIO' s 10-Year ROE (%) Range
Min: -111.61   Max: -3.63
Current: -98.28

-111.61
-3.63
ROA (%) -38.85
TBIO's ROA (%) is ranked higher than
59% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. TBIO: -38.85 )
TBIO' s 10-Year ROA (%) Range
Min: -72.54   Max: -2.7
Current: -38.85

-72.54
-2.7
ROC (Joel Greenblatt) (%) -314.91
TBIO's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. TBIO: -314.91 )
TBIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -282.88   Max: -4.92
Current: -314.91

-282.88
-4.92
Revenue Growth (%) -8.10
TBIO's Revenue Growth (%) is ranked higher than
63% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. TBIO: -8.10 )
TBIO' s 10-Year Revenue Growth (%) Range
Min: -23.5   Max: 9.9
Current: -8.1

-23.5
9.9
EBITDA Growth (%) 48.20
TBIO's EBITDA Growth (%) is ranked higher than
96% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. TBIO: 48.20 )
TBIO' s 10-Year EBITDA Growth (%) Range
Min: -54.7   Max: 71
Current: 48.2

-54.7
71
EPS Growth (%) 44.60
TBIO's EPS Growth (%) is ranked higher than
98% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.50 vs. TBIO: 44.60 )
TBIO' s 10-Year EPS Growth (%) Range
Min: -58.5   Max: 179.5
Current: 44.6

-58.5
179.5
» TBIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

TBIO Guru Trades in

TBIO Guru Trades in

Q2 2012

TBIO Guru Trades in Q2 2012

Ken Fisher 10,000 sh (New)
» More
Q3 2012

TBIO Guru Trades in Q3 2012

Ken Fisher Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2012-09-30 Sold Out $9 - $12.84 $ 2.39-79%0
Ken Fisher 2012-06-30 New Buy$9.36 - $13.56 $ 2.39-78%10000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.72
TBIO's P/B is ranked higher than
90% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.45 vs. TBIO: 1.72 )
TBIO' s 10-Year P/B Range
Min: 0.07   Max: 58.67
Current: 1.72

0.07
58.67
P/S 0.68
TBIO's P/S is ranked higher than
96% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. TBIO: 0.68 )
TBIO' s 10-Year P/S Range
Min: 0.04   Max: 1.59
Current: 0.68

0.04
1.59
EV-to-EBIT -1.94
TBIO's EV-to-EBIT is ranked higher than
69% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TBIO: -1.94 )
TBIO' s 10-Year EV-to-EBIT Range
Min: -4.2   Max: 24.5
Current: -1.94

-4.2
24.5
Current Ratio 1.40
TBIO's Current Ratio is ranked higher than
55% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.55 vs. TBIO: 1.40 )
TBIO' s 10-Year Current Ratio Range
Min: 0.96   Max: 18.01
Current: 1.4

0.96
18.01
Quick Ratio 1.03
TBIO's Quick Ratio is ranked higher than
52% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.12 vs. TBIO: 1.03 )
TBIO' s 10-Year Quick Ratio Range
Min: 0.67   Max: 17.35
Current: 1.03

0.67
17.35

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 5.69
TBIO's Price/Median PS Value is ranked higher than
61% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.34 vs. TBIO: 5.69 )
TBIO' s 10-Year Price/Median PS Value Range
Min: 0.49   Max: 12.2
Current: 5.69

0.49
12.2
Earnings Yield (Greenblatt) -51.50
TBIO's Earnings Yield (Greenblatt) is ranked lower than
53% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. TBIO: -51.50 )
TBIO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.1   Max: 267.2
Current: -51.5

4.1
267.2
Forward Rate of Return (Yacktman) 37.52
TBIO's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. TBIO: 37.52 )
TBIO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2022   Max: 56.9
Current: 37.52

-2022
56.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:A, ROP, GRMN, HXGBY, TRMB » details
Transgenomic Inc was incorporated in Delaware on March 6, 1997. The Company is a biotechnology company advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. Its operations are organized and reviewed by management along its product lines and presented in the following two complementary business segments: Laboratory Services and Genetic Assays and Platform. In Laboratory Services: its laboratories specialize in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. Its Patient Testing laboratories located in New Haven, Connecticut and Omaha, Nebraska are certified under the Clinical Laboratory Improvement Amendment ("CLIA") as high complexity laboratories and its Omaha facility is also accredited by the College of American Pathologists ("CAP"). Its laboratories employ genomic testing service technologies, including ICE COLD-PCR technology. ICE COLD-PCR is a proprietary platform technology that can be run in any laboratory with standard PCR technology and that enables detection of multiple unknown mutations from virtually any sample type including tissue biopsies, blood, cell-free DNA ("cfDNA") and circulating tumor cells ("CTCs") at levels greater than 1,000-fold higher than standard DNA sequencing techniques. In enetic Assays and Platforms: its proprietary product is the WAVE System, which has applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. It also distributes bioinstruments produced by other manufacturers ("OEM Equipment") through its sales and distribution network. The Company also distributes bioinstruments produced by other manufacturers ('OEM Equipment') through its sales and distribution network. Service contracts to maintain installed systems are sold and supported by its technical support personnel. The installed WAVE base and some OEM Equipment platforms generate a demand for consumables that are required for the continued operation of the bioinstruments. It develops, manufactures and sells these consumable products. In addition, it manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Competitors in these areas, among others, include Applied Biosystems, Qiagen, Roche, Sequenom and Illumina. Competition for some of its non-WAVE consumable products comes from numerous well-diversified life sciences reagent providers, including, among others, Invitrogen, Qiagen, Roche, Stratagene and Promega. The Company is subject to a variety of federal, state and municipal environmental and safety laws based on its use of hazardous materials in both manufacturing and research and development operations.
» More Articles for TBIO

Headlines

Articles On GuruFocus.com
Transgenomic, Inc. Reports Second Quarter 2009 Results Aug 12 2009 

More From Other Websites
TRANSGENOMIC INC Financials Nov 21 2014
Transgenomic Collaborates with Researchers to Advance Understanding of Genetic Disease Tuberous... Nov 19 2014
Transgenomic Collaborates with Researchers to Advance Understanding of Genetic Disease Tuberous... Nov 19 2014
10-Q for Transgenomic, Inc. Nov 14 2014
TRANSGENOMIC INC Files SEC form 10-Q, Quarterly Report Nov 12 2014
TRANSGENOMIC INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events,... Nov 05 2014
Transgenomic Announces Executive Changes Nov 05 2014
TRANSGENOMIC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Oct 30 2014
Transgenomic and University of Melbourne Collaborate to Further Validate Ability of Multiplexed ICE... Oct 30 2014
Transgenomic and University of Melbourne Collaborate to Further Validate Ability of Multiplexed ICE... Oct 30 2014
Transgenomic Reports Third Quarter 2014 Financial Results Oct 30 2014
Transgenomic to Hold Third Quarter Financial Results Conference Call on October 30, 2014 at 8:30AM... Oct 23 2014
Transgenomic Announces $2.375 Million Private Placement Financing Oct 22 2014
TRANSGENOMIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale... Oct 22 2014
Transgenomic Announces $2.375 Million Private Placement Financing Oct 22 2014
Transgenomic to Present at BTIG Emerging Technologies in Healthcare Diagnostics Conference Sep 24 2014
Transgenomic to Present at Fifth Annual Craig-Hallum Alpha Select Conference Sep 15 2014
Transgenomic to Present at Rodman & Renshaw 16th Annual Global Investment Conference Sep 05 2014
TRANSGENOMIC INC Files SEC form 10-Q, Quarterly Report Aug 08 2014
TRANSGENOMIC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK